IL6 and COVID-19: The current study focuses on IL-6 and CRP as potential biomarkers for PCC, as IL-6 is centrally involved in COVID-19 pathology as a pro-inflammatory marker (Batiha et al., 2022) and CRP is a sensitive marker of inflammation (Luan, Yin & Yao, 2021).